In 2022, 27 European Union/European Economic Area (EU/EEA) countries reported 731 echinococcosis cases. Of these, 299 (41%) cases were reported as Echinococcus granulosus sensu lato, 185 (25%) as E. multilocularis and 247 (34%) as an unknown species.
The objective of this review was to investigate the efficacy, effectiveness and safety of HPV vaccination in women undergoing conisation compared with those not receiving a HPV vaccination.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.